P2-055FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis

• Published in: Annals of oncology Vol. 30; no. Supplement_6
• Main Authors: Matsumoto, Toshihiko, Kimura, Shogo, Himei, Hitomi, Okazaki, Ukyo, Kurioka, Yusuke, Tsuduki, Takao, Takagi, Shijiro, Takatani, Masahiro, Hiramatsu, Ysushi, Morishita, Hirofumi
• Format: Journal Article
• Language: English
• Published: Oxford University Press 01.10.2019
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdz343.057

Abstract Background Although, FOLFIRINOX and nab-paclitaxel plus gemcitabine showed survival benefit in patients with advanced pancreatic cancer (APC) , there is no standard chemotherapy for APC after nab paclitaxel plus gemcitabine failure. Methods We retrospectively evaluated the efficacy and safety of FOLFIRINOX as salvage treatment in patients with APC refractory or intolerant to nab paclitaxel plus gemcitabine. Results Between July 2014 and October 2018, 23 patients received FOLFIRINOX after failure to nab-paclitaxel plus gemcitabine. The overall response rate (RR) was 23% and the disease control rate (DCR) was 68%. Median progression free survival (PFS) was 5.3 months (95% confidence interval (CI) 2.5-8.9 months ) and median overall survival (OS) was 12.1 months (95%CI : 4.0-14.2 months), 12 patients received FOLFIRINOX and 11 patients received modified FOLFIRINOX. In FOLFIRINOX group, RR was 9%, DCR was 73%, PFS was 5.3 months, and OS was 6.9 months. In modified FOLFORINOX group, RR was 23%, DCR was 64%, PFS was 4.3 months, and OS was 12.8 months. There was no significantly difference between both groups. And there was no significantly difference between both groups. Conclusion Second line chemotherapy with the FOLFIRINOX has a potential activity and is tolerable for APC who were failure to gemcitabine plus nab-paclitaxel.